What is the rationale for new treatment strategies in Alzheimer's disease?

CNS Spectrums
Michael A Rogawski

Abstract

Alzheimer's disease (AD) is characterized by the abnormal extracellular accumulation of amyloid beta-peptide (Abeta) into neuritic plaques and the intraneuronal aggregation of the microtubule-associated protein tau to form neurofibrillary tangles. These molecular events are implicated in the selective damage to neural systems critical for the brain functions that are impaired in AD. Impairment of cholinergic neurotransmission may be an important factor underlying the defects in cognition and memory that characterize AD. Cholinesterase (ChE) inhibitors, such as donepezil, rivastigmine, and galantamine, cause symptomatic improvement by inhibiting the breakdown of the neurotransmitter acetylcholine to increase its synaptic availability and, in the case of galantamine, by also allosterically potentiating nicotinic cholinergic receptors. Other agents, including vitamin E, monoamine oxidase inhibitors, and statins, have shown some benefit in epidemiological studies and clinical trials although compelling evidence of their efficacy is lacking. Memantine, shown to cause cognitive and functional improvement, is not an ChE inhibitor and does not interact with marketed ChE inhibitors. While the mechanism of action of memantine in AD is no...Continue Reading

Associated Clinical Trials

References

Apr 1, 1992·Neurology·R L Albin, J T Greenamyre
Apr 12, 1988·Neuroscience Letters·A NordbergB Winblad
Aug 1, 1993·Neurology·J RogersP Willson
Mar 1, 1997·Neurology·W F StewartE J Metter
Feb 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F X VollenweiderJ Angst
Feb 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·F X VollenweiderJ Angst
Jul 1, 1997·Neuroscience and Biobehavioral Reviews·W J Schmidt, B D Kretschmer
Jul 1, 1997·Neuroscience and Biobehavioral Reviews·W DanyszG Quack
Jul 15, 1997·Journal of Neuroscience Research·A Klegeris, P L McGeer
Feb 3, 1999·Annual Review of Genetics·D L PriceS S Sisodia
Mar 7, 2001·Biological Psychiatry·A H Rezvani, E D Levin
Mar 29, 2001·Physiological Reviews·D J Selkoe
Aug 29, 2001·Neurology·C FerrareseL Frattola
Aug 7, 2002·Clinical Pharmacokinetics·Michael W JannGary W Small
Oct 3, 2002·Nature Reviews. Neuroscience·Dale Schenk
Nov 5, 2002·Annual Review of Pharmacology and Toxicology·Dennis J Selkoe, Dale Schenk
Feb 7, 2003·Current Pharmaceutical Design·Kelly A ConwayAllen B Reitz
Mar 22, 2003·The Journal of Pharmacology and Experimental Therapeutics·Marek SamochockiAlfred Maelicke
May 13, 2003·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·Roberto Malinow
Jun 5, 2003·JAMA : the Journal of the American Medical Association·Paul S AisenUNKNOWN Alzheimer's Disease Cooperative Study
Jun 7, 2003·Annals of Nuclear Medicine·Karl Herholz
Aug 7, 2003·Expert Review of Vaccines·Dave Morgan
Sep 16, 2003·International Journal of Geriatric Psychiatry·Ezio Giacobini

❮ Previous
Next ❯

Citations

Feb 21, 2006·Doklady Biological Sciences : Proceedings of the Academy of Sciences of the USSR, Biological Sciences Sections·E I SolntsevaV G Skrebitsky
Jan 31, 2006·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Miran BrvarMatjaz Bunc
Oct 24, 2007·Journal of Gerontological Social Work·David E Vance, Thomas C Struzick

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.